Results 51 to 60 of about 2,803,213 (206)

A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease

Haematologica, 2020
The most common treatment for patients with sickle cell disease (SCD) is the chemotherapeutic hydroxyurea, a therapy with pleiotropic effects, including increasing fetal hemoglobin (HbF) in red blood cells and reducing adhesion of white blood cells to ...
James G. McArthur, Niels Svenstrup, Chunsheng Chen, Aurelie Fricot, Caroline Carvalho, Julia Nguyen, Phong Nguyen, Anna Parachikova, Fuad Abdulla, Gregory M. Vercellotti, Olivier Hermine, Dave Edwards, Jean-Antoine Ribeil, John D. Belcher, Thiago T. Maciel   +14 more
doaj   +1 more source

Phosphodiesterase-4 Inhibitors for Non-COPD Respiratory Diseases

Frontiers in Pharmacology, 2021
Selective phosphodiesterase (PDE) inhibitors are a class of nonsteroid anti-inflammatory drugs for treating chronic inflammatory diseases. Modulation of systemic and airway inflammation is their pivotal mechanism of action.
Theerasuk Kawamatawong
doaj   +1 more source

Mucin-inspired, high molecular weight virus binding inhibitors show biphasic binding behavior to influenza A viruses [PDF]

arXiv, 2020
Multivalent virus binding inhibitors are a promising new class of antivirals, preventing virus infection of cells by inhibiting the first step in the viral infection cycle - binding of viruses to the cell surface. The design of multivalent virus binding inhibitors is complex as many properties, such as inhibitor size and functionalization with virus ...
arxiv  

Women taking the “blue pill” (sildenafil citrate): such a big deal?

Drug Design, Development and Therapy, 2014
Giuseppe Lo Monte, Angela Graziano, Isabella Piva, Roberto Marci Department of Morphology, Surgery, and Experimental Medicine, University of Ferrara, Ferrara, Italy Abstract: For years, phosphodiesterase type 5 inhibitors have been used for the ...
Lo Monte G, Graziano A, Piva I, Marci R
doaj  

Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) and its inhibitors.

MedChemComm, 2017
Ecto-nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1, EC 3.1.4.1) is a metalloenzyme that belongs to the NPP family, which comprises seven subtypes (NPP1-7). NPP1 hydrolyzes a wide range of phosphodiester bonds, e.g.
Sang-Yong Lee, C. Müller
semanticscholar   +1 more source

Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática Tadalafil as treatment for idiopathic pulmonary arterial hypertension

Arquivos Brasileiros de Cardiologia, 2006
O uso de inibidores de fosfodiesterase, mais especificamente o sildenafil, no tratamento da hipertensão arterial pulmonar mostrou bons resultados, indicados por melhora dos parâmetros hemodinâmicos e da capacidade funcional.
Adriana Castro de Carvalho, André Luiz Hovnanian, Caio Julio César dos Santos Fernandes, Mônica Lapa, Carlos Jardim, Rogério Souza   +5 more
doaj   +1 more source

Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review

Pulmonary Circulation, 2020
Pulmonary Hypertension due to left heart disease is the most common type of Pulmonary Hypertension. Morbidity and mortality significantly increase once Pulmonary Hypertension is present.
Galo M. Sanchez Palacios, Cindy Schmidt, Tammy Wichman   +2 more
doaj   +1 more source

Newer treatments of psoriasis regarding IL‐23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors

Dermatologic Therapy, 2017
The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and Janus kinase (JAK) inhibitors are currently encouraging further ...
D. Wcisło-Dziadecka, M. Zbiciak-Nylec, L. Brzezińska-Wcisło, K. Bebenek, A. Kaźmierczak   +4 more
semanticscholar   +1 more source

Avanafil for erectile dysfunction in elderly and younger adults: differential pharmacology and clinical utility

Therapeutics and Clinical Risk Management, 2014
Eric G Katz,1 Ronny BW Tan,2 Daniel Rittenberg,1 Wayne J Hellstrom3 1Tulane University School of Medicine, New Orleans, LA, USA; 2Department of Urology, Tan Tock Seng Hospital, Singapore; 3Section of Andrology, Department of Urology, Tulane University ...
Katz EG, Tan RBW, Rittenberg D, Hellstrom WJ   +3 more
doaj  

Bayesian analysis of longitudinal studies with treatment by indication [PDF]

arXiv, 2019
It is often of interest in observational studies to measure the causal effect of a treatment on time-to-event outcomes. In a medical setting, observational studies commonly involve patients who initiate medication therapy and others who do not, and the goal is to infer the effect of medication therapy on time until recovery, a pre-defined level of ...
arxiv